Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools IDH-mutant glioma

IDH-mutant glioma

Programs, trials, and reported response and survival for IDH-mutant glioma.

Data as of 11.07.2026

All studies

Vorasidenib

NCT06478212

Servier · Phase 1/2 · Active, not recruiting · Enrollment 51

NCT06478212

Catalyst Primary completion. 11.2027. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

ArmReported safety

A count stays a count. This page does not turn a count into a percent.